Y-mAbs Therapeutics Inc. Completes Merger with Perseus BidCo US, Inc., Becoming Wholly Owned Subsidiary
Y-mAbs Therapeutics, Inc. has successfully merged with Yosemite Merger Sub, Inc., a subsidiary of Perseus BidCo US, Inc., following a cash tender offer of $8.60 per share for all outstanding shares. As a result, Y-mAbs will operate as a wholly owned subsidiary of Perseus BidCo US, Inc. This merger was initially announced on August 4, 2025.
Y-mAbs Therapeutics, Inc. has completed its merger with Yosemite Merger Sub, Inc., a wholly owned subsidiary of Perseus BidCo US, Inc. This follows the expiration of the cash tender offer at $8.60 per share for all outstanding shares of Y-mAbs common stock. As a result of the merger, Y-mAbs Therapeutics, Inc. will continue as a wholly owned subsidiary of Perseus BidCo US, Inc. The merger agreement was initially announced on August 4, 2025. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Y-mAbs Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-090232), on September 16, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here
